GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

GlaxoSmithKline (GSK) is conducting a Phase 3 clinical study titled A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease.

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte stimulator (BlyS)-specific ...

GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA approval for a 200 mg/mL autoinjector of Benlysta (belimumab) for the ...

December 18, 2019 – GSK announces BLISS–LN achieves primary endpoint and all major secondary endpoints in the phase 3 study of Benlysta in patients with lupus nephritis. December 17, 2020 – FDA ...

British pharmaceutical company GSK, which has its U.S. headquarters in Research Triangle Park, North Carolina, has partnered with HGS on Benlysta since 2006. The Lupus Foundation of America ...

Belimumab bested placebo in terms of SRI-4 response among patients treated for less than 2 years (OR = 1.38; P = .0219), and in those treated for 2 years or greater (OR = 1.85; P < .0001).

The Food and Drug Administration (FDA) has approved Benlysta (belimumab) for subcutaneous (SC) administration using an autoinjector in patients 5 years of age and older with active systemic lupus ...

Benlysta, known generically as belimumab, is given once a month by intravenous infusion. In the United States, the drug costs an average of $35,000 per patient a year.